Dr. Singh will summarize her research into Long-COVID, focusing on the first observations
of chronic sequelae of infection early in the pandemic and the subsequent development
of a local clinical program to treat patients with Long-COVID. She will outline the
NIH RECOVER program to establish a national program to study and define Long-COVID
and the program's recent successes. Finally, she will outline Stanford’s approach
to find treatments for Long-COVID with the description of the first global trial of
the use of an antiviral (Paxlovid) in the treatment of Long-COVID. She will outline
the rationale, study design, and lessons learned to date.2023 - Upinder Singh, MD, FIDSA
Upinder Singh, MD, FIDSA is Professor in the Departments of Internal Medicine and Microbiology and Immunology and Division Chief of Infectious Diseases and Geographic Medicine at the Stanford University School of Medicine. Dr. Singh is an international expert in infectious diseases. She is both a basic and a clinical scientist. Her basic science research focuses on the molecular and genomic applications of parasitic diseases, including Entamoeba histolytica and free-living amebae, and she has made many significant contributions to this field. Her clinical research has focused on COVID-19 and Long-COVID.
Dr. Matthew (Matt) Gevaert is the Chief Executive Officer, a Co-Founder and a Board
Member of Kiyatec, Inc. Under Matt’s leadership Kiyatec is disrupting cancer therapy
selection with patient-specific prediction of response to drug therapies, prior to
treatment. Kiyatec achieves this by measuring the response of individual patient live
cancer cells with its innovative 3D cell culture technology platform, with success
demonstrated in peer-reviewed publications for multiple tumor types that score >95th
percentile in on-line impact. Through a dedicated focus on direct relevance to cancer
patients, Kiyatec has successfully attracted multiple rounds of private sector investment,
developed its 3D PredictTM and KIYA-PredictTM ex vivo 3D cell culture platforms, and
published the first functional precision oncology assay with clinically-correlated
prospective predictive therapeutic response evidence in multiple tumor types. To-date,
Kiyatec has been awarded more than $5M of competitively awarded federal funding including
contracts from the National Cancer Institute, cultivated clinical collaborations at
leading national cancer institutions and built productive relationships with premier
biopharmaceutical companies developing the cancer therapies of the future. 
Dr. Chiriva Internati has been an Associate Professor at the MD Anderson Cancer Center
in Houston, Texas since August 2019. Prior to that, he served as an Associate Professor
at Texas Tech University Health Sciences Center from September 2013 to June 2017.
His research has led to the identification of novel cancer-testis antigens for the
development of immunotherapeutic strategies against solid and non-solid tumors. This
led to the development of the bioinformatic software Diamond CancerSplice, which is
a key core platform of our company, leading to the discovery and prioritization of
isoform antigens via insilico system.
Sarah Hallberg, DO, MS is the Medical Director at Virta Health, the first clinically-proven
treatment to safely and sustainably reverse type 2 diabetes without medications or
surgery.
Dr. Ian Crozier is a Vanderbilt-trained infectious diseases specialist originally
from Bulawayo, Zimbabwe. Over the past six years, primarily at the Infectious Diseases
Institute (Kampala, Uganda), his work has focused on developing clinical reasoning
skills in African clinicians providing complex care at African bedsides.
Stephen C. Dreskin, M.D., Ph.D. is a professor of Medicine and Immunology at the University
of Colorado School of Medicine-Denver and medical director of the University of Colorado
Allergy, Asthma, and Immunology Practice at the University of Colorado School of Medicine-Denver.